Search This Blog

Monday, December 31, 2018

Iovance Biotherapeutics initiated at B. Riley FBR


Iovance Biotherapeutics resumed with a Buy at B. Riley FBR. B. Riley FBR analyst George Zavoico resumed coverage of Iovance Biotherapeutics and kept his firm’s Buy rating and $24 price target on the shares.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)